concept

NEUROTOXICITY

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NEUROTOXICITY: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1210Connections

5Hypotheses

18Analyses

50Outgoing

50Incoming

0Experiments

20Debates

Summary

NEUROTOXICITY is a concept in neurodegeneration research. Key relationships include: activates, therapeutic target, associated with. Associated with ALS, Aging, Als. Connected to 676 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	NEUROTOXICITY
Key Genes/Proteins	ACHE, ACSL4, AGING, AKT, AKT1, ALOX12
Related Diseases	Aging, Als, Alzheimer
Related Pathways	Akt, Alpha-Synuclein

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Quinolinic Acid Neurotoxicity in Neurodegeneration

mechanism · 3699 words

→

Pathway Diagram

graph TD
    NEUROTOXICITY["NEUROTOXICITY"]
    NEUROTOXICITY -->|"activates"| Inflammation["Inflammation"]
    NEUROTOXICITY -->|"activates"| Als["Als"]
    NEUROTOXICITY -->|"activates"| Neuroinflammation["Neuroinflammation"]
    NEUROTOXICITY -->|"inhibits"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    NEUROTOXICITY -->|"inhibits"| Dementia["Dementia"]
    NEUROTOXICITY -->|"activates"| Parkinson["Parkinson"]
    NEUROTOXICITY -->|"activates"| Ms["Ms"]
    NEUROTOXICITY -->|"activates"| Neurodegeneration["Neurodegeneration"]
    SNCA["SNCA"] -->|"causes"| NEUROTOXICITY
    complement["complement"] -->|"activates"| NEUROTOXICITY
    PI3K_AKT["PI3K-AKT"] -->|"regulates"| NEUROTOXICITY
    catalase_mRNA["catalase mRNA"] -.protects against.-> NEUROTOXICITY
    impaired_autophagic_flux["impaired autophagic flux"] -->|"causes"| NEUROTOXICITY
    P62["P62"] -->|"inhibits"| NEUROTOXICITY
    DDX3X["DDX3X"] -->|"activates"| NEUROTOXICITY
    AMYOTROPHIC_LATERAL_SCLEROSIS["AMYOTROPHIC LATERAL SCLEROSIS"] -->|"inhibits"| NEUROTOXICITY
    PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] -->|"activates"| NEUROTOXICITY
    NEURODEGENERATION["NEURODEGENERATION"] -->|"activates"| NEUROTOXICITY

Outgoing (761)

Target	Relation	Type	Str
Inflammation	activates	disease	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
PARKINSON	therapeutic_target	gene	1.00
Aging	therapeutic_target	disease	1.00
Oxidative Stress	activates	pathway	1.00
NEUROINFLAMMATION	activates	gene	1.00
Als	activates	disease	1.00
Neurodegeneration	associated_with	disease	1.00
NEURODEGENERATION	activates	gene	1.00
Inflammation	therapeutic_target	disease	1.00
PARKINSON'S DISEASE	therapeutic_target	gene	1.00
Apoptosis	activates	pathway	1.00
ALZHEIMER'S DISEASE	therapeutic_target	gene	1.00
ALZHEIMER	activates	gene	1.00
ALZHEIMER	therapeutic_target	gene	1.00
CYTOKINES	activates	gene	1.00
Alzheimer	therapeutic_target	disease	1.00
Neuroinflammation	activates	disease	1.00
Als	therapeutic_target	disease	1.00
NEURODEGENERATION	therapeutic_target	gene	1.00
APOPTOSIS	activates	gene	1.00
MICROGLIA	activates	gene	1.00
Parkinson	therapeutic_target	disease	1.00
OXIDATIVE STRESS	activates	gene	1.00
Neurodegeneration	therapeutic_target	disease	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
NEURODEGENERATIVE DISEASES	activates	gene	1.00
Autophagy	activates	pathway	1.00
NEURODEGENERATIVE DISEASES	therapeutic_target	gene	1.00
AUTOPHAGY	activates	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
Nf-Κb	activates	pathway	1.00
Neuroinflammation	therapeutic_target	disease	0.95
MTOR	activates	gene	0.90
Ferroptosis	activates	pathway	0.90
PARKINSON'S DISEASE	activates	gene	0.90
NRF2	activates	gene	0.90
NEURON	activates	gene	0.90
NEUROINFLAMMATION	therapeutic_target	gene	0.90
TNF-Α	activates	gene	0.90
AMPK	activates	gene	0.90
OXIDATIVE STRESS	therapeutic_target	gene	0.90
TAU	activates	gene	0.90
Mtor	activates	pathway	0.90
NF-ΚB	activates	gene	0.90
AMYLOID	activates	gene	0.90
Oxidative Stress	therapeutic_target	pathway	0.90
Parkinson	activates	disease	0.85
Neurodegeneration	causes	process	0.85

Incoming (449)

Source	Relation	Type	Str
ROS	activates	gene	1.00
APOPTOSIS	activates	gene	1.00
Nanoparticles	causes	compound	0.95
Sevoflurane	causes	drug	0.95
Methamphetamine	causes	drug	0.95
LiCl	causes	compound	0.95
Oxidative Stress	causes	process	0.90
39814008	reduces	paper	0.90
SNCA	causes	gene	0.90
alpha-synuclein oligomers	causes	protein	0.90
Ion Imbalance	causes	process	0.90
MUTANT SOD1	causes	protein	0.90
Excitotoxicity	causes	process	0.90
Reactive Astrocytes	mediates	cell_type	0.90
Silver Nanoparticles	causes	compound	0.90
Titanium Dioxide Nanoparticles	causes	compound	0.90
PKN1-N207	contributes_to	protein	0.90
lithium chloride	causes	drug	0.90
AUTOPHAGY	activates	gene	0.90
BPA	causes	drug	0.88
Iron Overload	causes	phenotype	0.88
Gasdermin D	mediates	protein	0.85
Microglia	mediates	cell_type	0.85
mtDNA damage	contributes_to	phenotype	0.85
microglial_activation	contributes_to	mechanism	0.85
Neuroinflammation	contributes_to	process	0.85
Beta-Amyloid	causes	protein	0.80
A1_astrocytes	causes	cell_type	0.80
TP53	associated_with	gene	0.80
PLK2	enhances	gene	0.80
Microglia	contributes_to	cell_type	0.80
MITOPHAGY	activates	gene	0.80
APOPTOSIS	therapeutic_target	gene	0.80
catalase mRNA	protects_against	drug	0.70
autophagy	associated_with	process	0.70
complement	activates	protein	0.70
OxPCs	causes	biomarker	0.70
KEAP1	activates	gene	0.70
TREM2 deficiency	causes	gene	0.70
TREM2	protective_against	protein	0.70
PARP1 hyperactivation	causes	process	0.70
NEURODEGENERATION	activates	gene	0.70
GSDMD	activates	gene	0.70
APOPTOSIS	regulates	gene	0.70
24-hydroxycholesterol	causes	biomarker	0.70
mitophagy	prevents	process	0.70
tau-Gal3 co-aggregates	enhances	mechanism	0.70
Alpha-Synuclein Oligomers	causes	protein	0.70
tau	causes	protein	0.70
A1 astrocytes	causes	cell_type	0.70

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Selective LXRβ agonists restore ABCA1/ABCG1 expression and A	0.763	neuroscience	APOE4-driven lipid metabolism dysregulat
Microglial TREM2 Activation Reduces Amyloid-Associated Neuro	0.710	neurodegeneration	Test Preregistration Analysis
DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxici	0.634	neurodegeneration	Should microtubule-stabilizing drugs be
Gut Bacterial Metabolite-AhR Dysregulation Converts SCFA-Def	0.580	neurodegeneration	How does gut microbiome dysbiosis contri
TLR2 Recognition of Gut-Derived Fungal and Bacterial D-Alany	0.550	neurodegeneration	How does gut microbiome dysbiosis contri

Mentioning Analyses (18)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (20)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning NEUROTOXICITY in their description or question text

No additional research found

NEUROTOXICITY

Understanding Entity Pages

Summary

Wiki Pages (1)

Quinolinic Acid Neurotoxicity in Neurodegeneration

Pathway Diagram

Outgoing (761)

Incoming (449)

Targeting Hypotheses (5)

Mentioning Analyses (18)

De Novo Binder Design Targeting Alpha-Synuclein Aggregation Interface

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple

What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodege

How do oligodendrocytes initiate neuroinflammation in PD when microglia are trad

What is the high-resolution structure of the APOE4 hinge region and its role in

Do tau aggregates represent protective responses or primary pathogenic drivers i

Which neural cell types exhibit the most pronounced gene expression alterations

Do perinatal immune challenges create persistent epigenetic modifications that p

APOE4-driven lipid metabolism dysregulation in astrocytes and its role in AD

Neuroinflammation and microglial priming in early Alzheimer's Disease

Immune atlas neuroinflammation analysis in neurodegeneration

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

APOE4 targeting in neurodegeneration

Astrocyte Reactivity Subtypes in Neurodegeneration

Lipid raft composition changes in synaptic neurodegeneration

Neuroinflammation resolution mechanisms and pro-resolving mediators

Experiments (0)

Related Papers (0)

Debates (20)

Extended debate: CYP46A1 Overexpression Gene Therapy

Hypothesis debate: Membrane Cholesterol Gradient Modulators

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

What are effective therapeutic strategies for targeting APOE4 in Alzheimer's dis

APOE4 is the strongest genetic risk factor for late-onset AD. How APOE4 specific

The debate raised this developmental hypothesis but couldn't resolve the mechani

Can computational de novo protein binder design produce stable binders that bloc

The debate generated therapeutic hypotheses targeting different cell types but n

The debate highlighted fundamental disagreement about tau's role - whether aggre

Related Research